Department of Pediatrics, Division of Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Discipline of Paediatrics & Child Health, Randwick Clinical Campus, School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Sydney, New South Wales, Australia.
Pediatr Pulmonol. 2024 Sep;59 Suppl 1:S70-S80. doi: 10.1002/ppul.26913.
People with cystic fibrosis (pwCF) have an altered gastrointestinal microbiome. These individuals also demonstrate propensity toward developing small intestinal bacterial overgrowth (SIBO). The dysbiosis present has intestinal and extraintestinal implications, including potential links with the higher rates of gastrointestinal malignancies described in CF. Given these implications, there is growing interest in therapeutic options for microbiome modulation. Alternative therapies, including probiotics and prebiotics, and current CF transmembrane conductance regulator gene modulators are promising interventions for ameliorating gut microbiome dysfunction in pwCF. This article will characterize and discuss the current state of knowledge and expert opinions on gut dysbiosis and SIBO in the context of CF, before reviewing the current evidence supporting gut microbial modulating therapies in CF.
囊性纤维化（CF）患者的胃肠道微生物组发生了改变。这些患者也表现出易发生小肠细菌过度生长（SIBO）的倾向。目前存在的生态失调具有肠道和肠道外影响，包括与 CF 中描述的更高胃肠道恶性肿瘤发生率之间可能存在的联系。鉴于这些影响，人们对调节微生物组的治疗选择越来越感兴趣。替代疗法，包括益生菌和益生元，以及目前的 CF 跨膜电导调节因子基因调节剂，是改善 CF 患者肠道微生物组功能障碍的有前途的干预措施。本文将在回顾支持 CF 中肠道微生物调节治疗的现有证据之前，从 CF 的角度描述和讨论有关肠道生态失调和 SIBO 的当前知识状态和专家意见。
